Friday 6 November 2026 Export PFE’s income statement to Excel — free account

Pfizer Inc.

PFE Healthcare Drug Manufacturers General

Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.

Revenue: −0.43%
EPS: −7.98%
Free cash flow: +20.0%
Total debt: +1.55%

Quarter to September 2026, against a year earlier

29.27 0.18 −0.61%

Follow PFE

Alert me

Market cap: $170.3B
P/E: 42.2×
Fwd P/E: 18.9×
Dividend yield: 7.18%
F-score: 6/9
Altman Z: 2.03
Beneish M: −2.52
Dividend safety: 28/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Pfizer Inc. (PFE) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Pfizer Inc. (PFE) trades at a price to free cash flow of 15.5×. Over the past ten years it has ranged from 8.0× (October 2021) to 44.3× (July 2024); the current reading is higher than 56% of that period. That is below the Drug Manufacturers General industry median of 21.3× and below the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/PFE/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Pfizer Inc. price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/PFE/metrics/price-to-free-cash-flow">Pfizer Inc. (PFE) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	17.1×	2.82%
FY2024	16.6×	(60.41%)
FY2023	42.0×	268.69%
FY2022	11.4×	0.14%
FY2021	11.4×	(36.69%)
FY2020	18.0×	(14.70%)
FY2019	21.1×	15.12%
FY2018	18.3×	24.83%
FY2017	14.7×	5.55%
FY2016	13.9×	(3.14%)

Period	Price to free cash flow	Change
Sep 2026	14.8×	9.82%
Jun 2026	13.5×	(26.79%)
Mar 2026	18.4×	7.62%
Dec 2025	17.1×	13.05%
43 more quarters	Free account

Against its own ten years

Low 8.0× High 44.3×

Ten-year median 15.2×

Current reading's percentile 56

Company	Price to free cash flow
SNY Sanofi compare	6.7×
GSK GSK PLC Sponsored ADR compare	11.4×
BMY Bristol Myers Squibb Company compare	13.9×
GILD Gilead Sciences, Inc. compare	15.1×
PFE Pfizer Inc.	15.5×
NVS Novartis AG compare	21.7×
NVO Novo Nordisk A/S compare	23.5×
AMGN Amgen Inc. compare	27.3×
AZN AstraZeneca PLC compare	45.8×
Drug Manufacturers General industry median	21.3×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Pfizer Inc. (PFE) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on PFE

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on PFE

Stockrow Weekly